Phase III - International Pharmaceutical Industry

News

Positive Phase III results for plant-based COVID-19 vaccine

Medicago and GlaxoSmithKline (GSK) have announced positive efficacy and safety results from the global Phase III placebo-controlled efficacy study of Medicago’s plan...

7 December 2021 News COVID-19 vaccine | GlaxoSmithKline

Continue Reading →

News

Positive results for GSK’s anaemia drug daprodustat

GlaxoSmithKline (GSK) has revealed positive data for its investigational oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) daprodustat in patients...

9 November 2021 News anaemia | chronic kidney disease

Continue Reading →

News

Opdivo plus chemo improves event-free survival in NSCLC patients

Bristol Myers Squibb (BMS) has announced that its PD-1 inhibitor Opdivo (nivolumab) plus chemotherapy improved event-free survival in a Phase III trial in patients w...

9 November 2021 News BMS | Bristol Myers Squibb

Continue Reading →

News

AZ announces US fast track designation for IL-5 inhibitor Fasenra

AstraZeneca’s IL-5 inhibitor Fasenra (benralizumab) has received a fast-track designation from the US Food and Drug Administration for the treatment of eosinoph...

9 November 2021 News AstraZeneca | benralizumab

Continue Reading →

News

MHRA licenses Ryeqo for symptoms of uterine fibroids

The Medicines and Healthcare products Regulatory Agency (MHRA) has licensed Gedeon Richter UK’s Ryeqo (relugolix combination therapy) for the treatment of moderate t...

27 October 2021 News MHRA | Phase III

Continue Reading →

News

AstraZeneca’s long-acting antibody combination treats and prevents COVID-19

Positive high-level results from the TACKLE Phase III COVID-19 treatment trial have shown that AstraZeneca’s AZD7442, a long-acting antibody (LAAB) combination, achi...

13 October 2021 News antibody | AstraZeneca

Continue Reading →

News

Positive Phase III results for Lynparza plus abiraterone in metastatic prostate cancer

Positive high-level results from the PROpel Phase III trial have shown that AstraZeneca and MSD’s Lynparza (olaparib), in combination with abiraterone, dem...

29 September 2021 News AstraZeneca | homologous recombination repair

Continue Reading →

News

New tezepelumab data shows improvements for severe asthma subgroup

AstraZeneca and Amgen’s thymic stromal lymphopoietin (TSLP) blocker tezepelumab has demonstrated new improvements for patients with severe asthma and comorbid nasal ...

8 September 2021 News amgen | AstraZeneca

Continue Reading →

News

Phase III data for Jardiance shows improvement in HFpEF patients

Results from the EMPEROR-Preserved Phase III trial have shown that Jardiance (empagliflozin) demonstrated a 21% relative risk reduction of cardiovascular death or ho...

1 September 2021 News cardiovascular death | empagliflozin

Continue Reading →

News

Dupixent trial meets endpoints for childhood eczema

The Phase III trial for Sanofi/Regeneron's Dupixent (dupilumab) plus topical corticosteroids (TCS) for the treatment of moderate-to-severe atopic dermatitis (eczema)...

1 September 2021 News aged six months to five years | atopic dermatitis

Continue Reading →